Physician profile
Kumar K Batra
NPI 1770891566
$1,422.88
in general payments reported to CMS, 2019-2025
22 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2021: $50.89 · 2022: $34.12 · 2023: $392 · 2024: $407 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.13 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $416.37 | 2019-2025 | Kadcyla, Perjeta, Phesgo |
| Lilly USA, LLC | $164.85 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $125.54 | 2019-2023 | Opdivo |
| Celgene Corporation | $65.30 | 2023 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $65.19 | 2024-2025 | |
| Mirati Therapeutics, INC. | $54.32 | 2024 | Krazati |
| Merck Sharp & Dohme LLC | $53.94 | 2023-2025 | Keytruda, Lynparza |
| Adaptive Biotechnologies Corporation | $49.51 | 2025 | Clonoseq |
| Springworks Therapeutics, INC. | $48.45 | 2024 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $43.01 | 2022-2023 | Advate |
| Pharmacyclics LLC, An Abbvie Company | $42.86 | 2019 | |
| Gilead Sciences, INC. | $41.84 | 2021-2024 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $34.64 | 2024 | |
| Amgen INC. | $31.03 | 2023 | |
| Genzyme Corporation | $27.98 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $27.81 | 2025 | |
| Daiichi Sankyo INC. | $26.21 | 2024 | Enhertu |
| Incyte Corporation | $25.94 | 2025 | Jakafi |
| Pfizer INC. | $25.93 | 2025 | |
| Emd Serono, INC. | $21.00 | 2024 | |
| Astellas Pharma US INC | $20.87 | 2021 | |
| Pharmaand Gmbh | $10.29 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.